Home / Ophthalmology
Ophthalmology
| 2 min read
Biotechnology acquisitions in the U.S. totaled $28.5 billion last year, driven by Takeda Pharmaceutical Co. and Eli Lilly & Co. purchases made to bolster their product offerings, according to a recent report by Ernst & Young Global Ltd.
| 3 min read
Jerini Ophthalmic and PR Pharmaceuticals to develop sustained-release formulations for eye diseases
| 1 min read
Alpha Innotech to create new device for OEM agreement with R&C Biogenius
| 2 min read
In a pair of in-licensing deals with Archemix Corp. and OSI Pharmaceuticals, Ophthotech Corp. recently acquired rights to aptamer compounds for the treatment of macular degeneration. Ophthotech is a new company formed by former executive of Eyetech, which OSI Pharmaceuticals acquired in late 2005.
| 1 min read
| 1 min read
Because many ocular diseases have genetic origins, the eye has become a popular target for gene therapy. Concerns about viral vectors, however, led researchers at Copernicus Therapeutics
| 3 min read
BOSTON–A new collaboration between CombinatoRx Inc. and Fovea Pharmaceuticals SA will provide Fovea with combination drug candidates for ophthalmic disorders from CombinatoRx’s portfolio. The program will explore using approved drugs in tandem to generate novel mechanisms of action that create new treatments for ophthalmic diseases.
| 1 min read
Five-year-old sequencing company VisiGen Biotechnologies got a big shot in the arm recently with an equity investment and collaboration deal with Applied Biosystems Group. Concurrent with the Applied Bio deal, VisiGen also secured additional capital from its current investor DNA technology services company SeqWright Inc. Exact figures of the investements were not released.
